A literature review of the patent application publications on cabotegravir – an HIV integrase strand transfer inhibitor

References

• World Health Organization: Global summary of the AIDS epidemic [Internet]. [ cited 2019 Oct 15]. Available from: https://www.who.int/hiv/data/en/.
   Google Scholar
• HIV Cure [Internet]. [ cited 2019 Oct 15]. Available from: https://www.niaid.nih.gov/diseases-conditions/hiv-cure-research.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [Internet]. [ cited 2019 Oct 15]. Available from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV Type 1 drug resistance detection. Clin Infect Dis. 2009;50:98–105.
   Web of Science ®Google Scholar
• Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–1307.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services: AIDS info [Internet]. [ cited 2019 Oct 15]. Available from: https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/73/the-hiv-life-cycle.
   Google Scholar
• Guidelines for the use of Antiretroviral Agents in Adults and Adolescents with HIV [Internet]. [ cited 2019 Oct 15]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
   Google Scholar
• Puras Lutzke RA, Eppens NA, Weber PA, et al. Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. Proc Natl Acad Sci. 1995;92:11456–11460.
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–650.
   PubMed Web of Science ®Google Scholar
• Delelis O, Carayon K, Saïb A, et al. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008;5:114.
   PubMed Web of Science ®Google Scholar
• Xiang L, Krishnan L, Cherepanov P, et al. Structural biology of retroviral DNA integration. Virology. 2011;411:194–205.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Zhao XZ, Burke Jr TR, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15:37.
   PubMed Web of Science ®Google Scholar
• Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2013;10:279–290.
   Web of Science ®Google Scholar
• Hare S, Smith SJ, Metifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80:565–572.
   PubMed Web of Science ®Google Scholar
• Evering TH, Markowitz M. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs. 2008;17:413–422.
   PubMed Web of Science ®Google Scholar
• Anker M, Corales RG. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs. 2008;17:97–103.
   PubMed Web of Science ®Google Scholar
• Evering TH, Markowitz M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today. 2007;43:865–877.
   PubMed Web of Science ®Google Scholar
• Reviriego C. Elvitegravir for the treatment of HIV. Drugs Today. 2014;50:209–217.
   PubMed Web of Science ®Google Scholar
• Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012;21:395–401.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Quashie P, Mesplède T. Dolutegravir: HIV integrase inhibitor treatment of HIV infection. Drugs Future. 2012;37:697–707.
   Web of Science ®Google Scholar
• Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012;21:523–530.
   PubMed Web of Science ®Google Scholar
• Markham A. Bictegravir: first global approval. Drugs. 2018;78:601–606.
   PubMed Web of Science ®Google Scholar
• Han Y, Mesplède T, Wainberg MA. Cabotegravir. Drugs Future. 2015;40:705–715.
   Web of Science ®Google Scholar
• McPherson TD, Sobieszczyk ME, Markowitz M. Cabotegravir in the treatment and prevention of human immunodeficiency virus-1. Expert Opin Investig Drugs. 2018;27:413–420.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS. 2015;10:246–252.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Hoffmann C. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis. Curr Opin HIV AIDS. 2018;13:334–340.
   PubMed Web of Science ®Google Scholar
• Patel M, Eberl HC, Wolf A, et al. Mechanistic basis of cabotegravir–glucuronide disposition in humans. J Pharmacol Exp Ther. 2019;370:269–277.
   PubMed Web of Science ®Google Scholar
• Trezza C, Ford SL, Spreen W, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10:239–245.
   PubMed Web of Science ®Google Scholar
• Zhou T, Su H, Dash P, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018;151:53–65.
   PubMed Web of Science ®Google Scholar
• Pons-Faudoa FP, Sizovs A, Trani ND, et al. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. J Control Release. 2019;306:89–96.
   PubMed Web of Science ®Google Scholar
• Fulcher JA, Tamshen K, Wollenberg AL, et al. Human vault nanoparticle targeted delivery of antiretroviral drugs to inhibit human immunodeficiency virus type 1 infection. Bioconjug Chem. 2019;30:2216–2227.
   PubMed Web of Science ®Google Scholar
• Gendelman HE, McMillan J, Bade AN, et al. The promise of long-acting antiretroviral therapies: from need to manufacture. Trends Microbiol. 2019;27:593–606.
   PubMed Web of Science ®Google Scholar
• Andrews CD, Bernard LST, Poon AY, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. Aids. 2017;31:461–467.
   PubMed Web of Science ®Google Scholar
• Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Curr Opin HIV AIDS. 2015;10:258–263.
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:11.
   Web of Science ®Google Scholar
• Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV/AIDS - Res Palliat Care. 2016;8:157–164.
   Google Scholar
• Singh K, Sarafianos SG, Sönnerborg A. Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and integrase. Pharmaceuticals. 2019;12:62.
   Web of Science ®Google Scholar
• Fernandez C, van Halsema CL. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS - Res Palliat Care. 2019;11:179–192.
   Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
   PubMed Web of Science ®Google Scholar
• Murray MI, Markowitz M, Frank I, et al. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial. HIV Clin Trials. 2018;19:129–138.
   PubMed Web of Science ®Google Scholar
• Smith RA, Wu VH, Zavala CG, et al. In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother. 2018;62:1–8.
   Google Scholar
• Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus–uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70(2):319-322.
   PubMed Web of Science ®Google Scholar
• Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61(12):1–9.
   Web of Science ®Google Scholar
• Oliveira M, Ibanecsu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15:56.
   PubMed Web of Science ®Google Scholar
• Radzio-Basu J, Council O, Cong M, et al. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nat Commun. 2019;10:2005.
   PubMed Web of Science ®Google Scholar
• Johns BA, Kawasuji T, Taishi T, et al., inventor; Shionogi & Co., Ltd., assignee. Polycyclic carbamoylpyridone derivate having HIV integrase inhibitory activity. WO 2006/116764 A1. 2006.
   Google Scholar
• Yoshida H, Taoda Y, Johns BA., inventor; Shionogi & Co., Ltd., GlaxoSmithKline Llc., assignee. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates. WO 2010/068253 A1. 2010.
   Google Scholar
• Johns BA, Duan M, Hakogi T., inventor; Shionogi & Co., Ltd., GlaxoSmithKline Llc., assignee. Process and intermediates for carbamoylpyridone HIV integrase inhibitors. WO 2010/068262 A1. 2010.
   Google Scholar
• Wang H, Goodman SN, Mans D, et al., inventor; GlaxoSmithKline Llc., assignee. Process for preparing carbamoylpyridone derivates and intermediates. WO 2011/119566 A1. 2011.
   Google Scholar
• Sumino Y, Okamoto K, Masui M, et al., inventor; Shionogi & Co., Ltd., assignee. Process for preparing compound having HIV integrase inhibitory activity. WO 2012/018165 A1. 2012.
   Google Scholar
• Hughes DL. Review of synthetic routes and final forms of integrase inhibitors dolutegravir, cabotegravir, and bictegravir. Org Process Res Dev. 2019;23:716–729.
   Web of Science ®Google Scholar
• Mundhra DB, Pan R., inventor; GlaxoSmithKline Llc., assignee. Pharmaceutical compositions. WO 2012/037320 A2. 2012.
   Google Scholar
• Edagwa BJ, Gendelman HE, Johns BA., inventor; Viiv Healtcare Company, Board of regents of the University of Nebraska, assignee. Compositions and methods for the delivery of therapeutics. WO 2017/223280 A2. 2017.
   Google Scholar
• Gendelman HE, Liu XM., inventor; The board of regents of the University of Nebraska, assignee. Compositions and methods for the delivery of therapeutics. WO 2015/127437 A1. 2015.
   Google Scholar
• Rome L, Buehler D, Maynard HD., inventor; The regents of the University of California, assignee. Vaults engineered for hydrophobic drug delivery. WO 2015/058025 A1. 2015.
   Google Scholar
• Karp JM, Joshi N, Rioux D, et al., inventor; The Brigham and women’s hospital, Inc., assignee. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof. WO 2018/144991 A1. 2018.
   Google Scholar
• Grauwels H, Margolis D, Spaltenstein A, et al., inventor; Viiv HealthCare Company, Janssen Science Ireland unlimited Company, assignee. Regimens for treating HIV infections and AIDS. WO 2019/016732 A1. 2019.
   Google Scholar
• Spreen WR., inventor; Viiv HealthCare Company, assignee. Combinations and uses treatments thereof. WO 2017/205585 A1. 2017.
   Google Scholar
• Underwood MR., inventor; GlaxoSmithKline Llc., assignee. Antiviral therapy. WO 2011/094150 A1. 2011.
   Google Scholar
• Scott TR., inventor; Viiv HealthCare Company, assignee. Combination drug therapy. WO 2019/016679 A1. 2019.
   Google Scholar
• Rao DR, Malhotra G, Sawant AA, et al., inventor; Cipla Limited, assignee. Process for preparing polycyclic carbamoyl pyridone derivates and intermediates thereof. WO 2015/177537 A1. 2015.
   Google Scholar
• Mara šN, Seli čL, Čusak A., inventor; Lek Pharmaceuticals d.d., assignee. Process for preparing dolutegravir and cabotegravir and analogues thereof. WO 2016/113372 A1. 2016.
   Google Scholar
• Singh GP, Shrivastava D, Jadhav HS, et al., inventor; Lupin Limited, assignee. Process for the preparation of HIV integrase inhibitors. WO 2017/109649 A1. 2017.
   Google Scholar
• Adamer V, Thaler A., inventor; Sandoz AG, assignee. Crystalline forms of cabotegravir sodium. WO 2018/149608 A1. 2018.
   Google Scholar
• Phull MS, Thoppil SJ, Tarate SN, et al., inventor; Cipla Limited, assignee. Novel polymorphs and salts of polycyclic carbamoyl pyridone derivates. WO 2018/109786 A1. 2018.
   Google Scholar
• Champion CI, Kickhoefer VA, Liu G, et al. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One. 2009;4:4.
   Web of Science ®Google Scholar
• Qingfeng D, Yan Z, Tao G., inventor; YaoPharma Co. Ltd, assignee. Pharmaceutical composition for preventing and treating HIV infection. CN 109568328 A. 2019.
   Google Scholar
• Malhotra G, Joshi K, Raut P, et al., inventor; Cipla Limited, assignee. Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer. WO 2017/138022 A1. 2017.
   Google Scholar
• Gulick RM, Flexner C. HIV drugs for treatment, and for prevention. Annu Rev Med. 2019;70:137–150.
   PubMed Web of Science ®Google Scholar
• Yu Z, Zhang L, Chu H, et al., inventor; Dairy cattle research center of Shandong academy of agricultural sciences, assignee. Cabotegravir. CN 109646440 A. 2019.
   Google Scholar
• ViiV Healthcare seeks US approval of long-acting, injectable HIV treatment [Internet]. [ cited 2019 Oct 15]. Available from: http://www.firstwordpharma.com/node/1637411#axzz5vC4GUkeE.
   Google Scholar
• ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational Cabotegravir to Be Used in Combination With Rilpivirine as the First Monthly, Injectable Treatment for HIV [Internet]. [ cited 2019 Dec 15]. Available from: https://viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-submits-regulatory-application-to-european-medic/.
   Google Scholar